

PeptiDream announces new PDC collaboration with Novartis

28 June 2019 | News | By Hithaishi CB

Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel macrocyclic/constrained peptides for use as Peptide-Drug Conjugates (PDCs) against multiple targets of interest selected by Novartis



PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, on 27 June 2019, announced a new Peptide Drug Conjugate “PDC” collaboration agreement with Swiss-based Novartis. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology for the identification of novel macrocyclic/constrained peptides for use as PDCs against multiple targets of interest selected by Novartis. Novartis will have exclusive rights to the program peptides for radionuclide payloads/conjugates and certain small molecule payloads/conjugates, for both therapeutic and diagnostic uses.

Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, R&D funding payments, and is eligible to receive additional pre-clinical, clinical, approval, and commercial sales milestones, as well as royalties on future sales of any commercialized products resulting from the collaboration.

The long-standing macrocyclic peptide discovery alliance between the companies was originally initiated in 2012 and has been extended/amended/expanded multiple times since, including a non-exclusive license to PeptiDream’s PDPS technology in 2015.

“We are extremely excited to be working with Novartis on peptide drug conjugates, specifically on peptide-radionuclide conjugates, in which Novartis is one of the leading companies in the space. Our macrocyclic/constrained peptides are ideal for the delivery of conjugated payloads, either therapeutic or diagnostic, specifically to the targeted cells/tissues and we believe this partnership has the potential to bring a number of first-in-class and best-in-class therapeutics and their companion diagnostics to patients worldwide” said Patrick Reid, CEO of PeptiDream Inc.